Vorinostat is the first HDAC inhibitor approved in 2006 for cutaneous T-cell lymphoma (CTCL), with an ORR of 29.7% (22/74) (Olsen et al., 2007). This evidence concerns the gene HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma.